Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life.
Burden of disease
Conceptual model
HCM symptoms
Hypertrophic cardiomyopathy
Patient-reported outcomes
Quality of life
Shortness of breath
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
28
07
2020
accepted:
18
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients' perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients' experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them. Development of the HCM conceptual model involved a web-based survey to capture patients' insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients' experiences were identified and used to develop a conceptual model of the patient experience with HCM. The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients' lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM. A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients' lives. This HCM conceptual model reflecting patients' experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients' perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients' experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them.
METHODS
METHODS
Development of the HCM conceptual model involved a web-based survey to capture patients' insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients' experiences were identified and used to develop a conceptual model of the patient experience with HCM.
RESULTS
RESULTS
The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients' lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM.
CONCLUSIONS
CONCLUSIONS
A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients' lives. This HCM conceptual model reflecting patients' experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.
Identifiants
pubmed: 33259041
doi: 10.1186/s41687-020-00269-8
pii: 10.1186/s41687-020-00269-8
pmc: PMC7708573
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102Références
Circulation. 2011 Dec 13;124(24):2761-96
pubmed: 22068435
J Am Heart Assoc. 2018 Feb 25;7(5):
pubmed: 29478967
Genet Med. 2010 Nov;12(11):655-67
pubmed: 20864896
Am Heart J. 2015 Jul;170(1):87-95, 95.e1-4
pubmed: 26093868
Circ Heart Fail. 2015 Nov;8(6):1022-31
pubmed: 26374874
Am Heart J. 2015 May;169(5):684-692.e1
pubmed: 25965716
Am J Med. 2016 May;129(5):486-496.e2
pubmed: 26800575
Heart. 1997 Aug;78(2):182-7
pubmed: 9326995
Am J Med Genet A. 2009 Feb 15;149A(4):602-12
pubmed: 19253387
Am J Cardiol. 2000 Jul 15;86(2):162-8
pubmed: 10913477
Catheter Cardiovasc Interv. 2016 Nov 15;88(6):953-960
pubmed: 27143093
Am J Cardiol. 2012 May 15;109(10):1494-8
pubmed: 22356797
J Am Coll Cardiol. 1993 Jun;21(7):1672-9
pubmed: 8496536
Open Heart. 2016 Oct 17;3(2):e000488
pubmed: 27843566
Am J Cardiol. 2016 Mar 15;117(6):961-5
pubmed: 26810858
Circulation. 2015 Jul 7;132(1):10-9
pubmed: 25977310
JACC Heart Fail. 2015 May;3(5):408-418
pubmed: 25863972
Am J Cardiol. 2013 Oct 15;112(8):1182-9
pubmed: 24079444
Circulation. 2009 Mar 3;119(8):1085-92
pubmed: 19221222
Int J Cardiol. 2015 Apr 1;184:743-9
pubmed: 25827935
Heart Lung Circ. 2011 Nov;20(11):688-90
pubmed: 22000299
Am J Cardiol. 2013 Apr 1;111(7):1034-9
pubmed: 23340032
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
Health Qual Life Outcomes. 2016 Apr 14;14:62
pubmed: 27079917
JAMA. 2017 Apr 4;317(13):1349-1357
pubmed: 28306757
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
J Am Coll Cardiol. 2013 Jul 30;62(5):449-57
pubmed: 23643593
N Engl J Med. 2003 Jan 23;348(4):295-303
pubmed: 12540642
Open Heart. 2016 Jul 20;3(2):e000484
pubmed: 27547438
N Engl J Med. 2016 Jun 23;374(25):2441-52
pubmed: 27332903
Circulation. 2016 Jan 5;133(1):62-73
pubmed: 26518766
Circulation. 2003 Oct 28;108(17):e118-21
pubmed: 14581388